Before the introduction of prophylactic ganciclovir therapy to minimize the risk of cytomegalovirus disease in allogeneic marrow transplant recipients, CMV interstitial pneumonitis was a major cause of mortality. We first reported the beneficial impact of ganciclovir prophylaxis in marrow allograft recipients in 1991 1 and this was subsequently confirmed in two prospective randomized trials. 2, 3 In the current study, we compared the pattern of interstitial pneumonitis in allogeneic recipients transplanted at St Vincent's Hospital, Sydney prior to the introduction of prophylactic ganciclovir (in June 1989) with that seen in patients transplanted after that date and given prophylactic ganciclovir.
Patients and methods
All patients in this study received an HLA-identical family member, an HLA-partially identical family member, or an HLA-identical unrelated bone marrow transplant for hematological malignancy after marrow-ablative chemotherapy or chemoradiotherapy between February 1981 and June 1995. In June, 1989, we introduced ganciclovir prophylaxis to minimize the risk of cytomegalovirus disease for all marrow allograft recipients at risk by virtue of the recipient, 4 or the donor, 5 or both, being seropositive for CMV prior to transplant. The first 26 patients to receive prophylactic ganciclovir have been previously reported. 1 Clinical details of the patients in the group given prophylactic ganciclovir and in the group not given prophylactic ganciclovir are shown in Table 1 .
Interstitial pneumonitis was diagnosed by open lung or transbronchial biopsy. Tissue was examined in the histopathological laboratory by hematoxylin and eosin staining, CMV early antigen immunoperoxidaze staining, methenamine silver staining for Pneumocystis carinii and PAS staining for fungal organisms. In the microbiological laboratory Gram staining was performed, as well as a ZN stain, a Legionella direct fluorescence stain, an indirect fluorescence stain for Pneumocystis carinii and the following: bacterial culture including aerobes, anaerobes, AFB, Legionella and norcardia; fungal culture, viral culture, and chlamydial culture. Acute graft-versus-host disease (GVHD) was diagnosed using clinical and histological criteria previously published. 6, 7 Prophylactic ganciclovir was scheduled pre-and posttransplant from June 1989 onwards for all patients who were CMV seropositive pre-transplant. It was scheduled for post-transplant administration to CMV seronegative recipients given marrow from CMV seropositive donors (CMV seronegative donor-recipient pairs were not given prophylactic ganciclovir; CMV prophylaxis in these patients comprised the use of CMV seronegative blood products preand post-transplant).
Ganciclovir was given at a dose of 5 mg/kg twice daily as an intravenous infusion from day −8 to day −1 pre-transplant inclusive. Administration was then stopped until day 21 post-transplant or until such time as the neutrophil count was 1 × 10 9 /l or greater (whichever was later). The posttransplant dose of ganciclovir was 5 mg/kg given on 3 week days each week until day 84 post-transplant. Ganciclovir was withheld post-transplant if the platelet count dropped to less than 20 × 10 9 /l or the absolute neutrophil count to less than 0.5 × 10 9 /l. Ganciclovir dosage was reduced for renal function impairment according to the manufacturer's instructions (Syntex, Sydney, Australia).
Statistical analysis
The actuarial probability of acquiring interstitial pneumonitis was determined by Kaplan-Meier plots. 8 Differences between the two groups were evaluated by using a MannWhitney U test in the case of continuous variables (eg age) and 2 test in the case of categorical variables (eg sex, diagnosis, conditioning regimen, GVHD prophylaxis, incidence of acute GVHD and CMV status).
A logistic regression analysis was carried out to determine significant risk factors for CMV IP. Logistic regression was judged to be the most appropriate procedure for these data because the incidence of CMV IP in the first 100 days post-transplant has a clear dichotomous zero-one distribution. The dependent variable was presence of CMV IP (1 = patient contracted CMV IP, 0 = patient did not contract CMV IP), and there were 16 independent variables. Actuarial overall survival was determined using KaplanMeier plots. 8 
Results

Incidence of interstitial pneumonitis
The overall incidence of interstitial pneumonitis for patients not receiving prophylactic ganciclovir (n = 280) was 19.6%, while it was 12.5% for those receiving prophylactic ganciclovir (n = 176) (P = 0.03) (Figure 1a and Figure 2 ). This reduction in the overall incidence of IP was due primarily to reduction in the incidence of CMV-IP.
Incidence of cytomegalovirus interstitial pneumonitis
The incidence of CMV-IP was 12.9% in those not receiving prophylactic ganciclovir vs 1.7% in those receiving prophylactic ganciclovir (P Ͻ 0.005) (Figure 1b) .
Idiopathic interstitial pneumonitis
The incidence of idiopathic IP in those receiving ganciclovir was 6.3%, while it was 3.2% in those not receiving ganciclovir (P = 0.19) (Figure 1c) .
Incidence of Pneumocystis carinii interstitial pneumonitis
The incidence of IP due to Pneumocystis carinii was 2.9% in those not receiving ganciclovir and 0.6% in those receiving ganciclovir (P = 0.09) (Figure 1d ). 
Type of interstitial pneumonitis
Cytomegalovirus IP accounted for 65.5% of all IP in patients not receiving ganciclovir vs 13.6% of cases in those receiving prophylactic ganciclovir. The most common type of IP in those receiving prophylactic ganciclovir was idiopathic IP (50%) ( Table 2) . 
Primary cause of death
The primary cause of death is shown in Table 3 . In patients not given ganciclovir CMV-IP was the primary cause of death in 30.9% (17 of 55 patients), whereas CMV-IP was the primary cause of death in 4.5% in those given prophylactic ganciclovir (P = 0.01) ( Table 3) .
Logistic regression analysis of factors predisposing to CMV-IP
A logistic regression analysis was carried out with the incidence of CMV IP as the dependent variable and 16 independent variables including ganciclovir prophylaxis, recipient age, recipient sex, diagnosis, disease stage at transplant, donor age, donor-recipient sex combinations, HLA-match, conditioning regimen, CMV serological status of recipient, CMV serological status of donor and incidence of acute GVHD grade II or higher.
The results from this regression indicated that ganciclovir prophylaxis was a significant factor in reducing the incidence of CMV IP (P = 0.001). Busulphan/ cyclophosphamide conditioning was also a significant factor in reducing the incidence of CMV IP (P = 0.04). The presence of acute GVHD grade II or higher was a significant risk factor for CMV IP (P Ͻ 0.0005).
Survival
Overall survival was identical between the two groups (P = 0.86) (Figure 3) .
Discussion
This study confirms that prophylactic ganciclovir has reduced the incidence and mortality rate from cytomegalovirus interstitial pneumonitis and in doing so has decreased the overall incidence of interstitial pneumonitis after allogeneic marrow transplantation. This was not a randomized study but rather a retrospective comparison of two sequential cohorts before and after the introduction of prophylactic ganciclovir therapy for patients at risk of CMV disease in our program. Other aspects of treatment changed during this time period including a switch from cyclophosphamide and total body irradiation conditioning for matched sibling transplantation to busulphan and cyclophosphamide 9 and the utilization of combination cyclosporin and methotrexate (in 1986) rather than single agent immune suppression. 10 In the logistic regression analysis, busulphan/cyclophosphamide conditioning was found to be an independent variable for reducing the incidence of CMV-IP as was the use of prophylactic ganciclovir. Grade II/IV acute graftversus-host disease was found to be a risk factor for CMV- Table 4 Risk factors for development of CMV IP IP as has been previously described, 4 but the cyclosporin/methotrexate regimen did not have a significant impact on this. There was no difference in survival between the ganciclovir group and the group not receiving ganciclovir, but a number of factors may have been responsible for this lack of improvement in survival including differences between the two groups for age, diagnosis/status, conditioning regimen, GVHD prophylaxis regimen, incidence and severity of acute GVHD and cytomegalovirus serological status.
Idiopathic interstitial pneumonitis is now the most common single cause of IP after allogeneic marrow transplantation in our practice. This is normally thought to be due to the high-dose pre-transplant conditioning regimen and often responds satisfactorily to corticosteroid treatment. Occasionally a similar syndrome has been described and attributed to acute graft-versus-host disease involving the pulmonary parenchyma.
11 It remains our view that it is important to obtain a tissue diagnosis of interstitial pneumonitis, although given the low incidence of CMV-IP and PCP-IP, some might take an alternative view. A reasonable compromise at the present time may be to use the transbronchial approach for lung biopsy and to take multiple samples from several lobes in order to maximize the diagnostic yield.
